Skip to main content

Table 5 Treatment-emergent adverse events (≥5 % in either group), safety population: carrier study

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Event PBO + BAP 0.5 (n = 215) BAP 0.5 + BAP 0.5 (n = 275)
ARIA-E (vasogenic cerebral edema) 23 (10.7) 10 (3.6)
Cerebral microhemorrhage 20 (9.3) 15 (5.5)
Headache 16 (7.4) 8 (2.9)
Diarrhea 12 (5.6) 10 (3.6)
Urinary tract infection 12 (5.6) 9 (3.3)
Anxiety 11 (5.1) 7 (2.5)
  1. Data presented as n (%)
  2. ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo